Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse

Martin S. Tallman, David Hakimian, Kenneth J. Kopecky, Susan Wheaton, Eric Wollins, Kathy Foucar, Peter A. Cassileth, Thomas Matthew Habermann, Michael Grever, Jacob M. Rowe, LoAnn C. Peterson

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

The purine nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2'- deoxycoformycin (2'-DCF) induce complete remission (CR) in the majority of patients with hairy cell leukemia. However, minimal residual disease (MRD) has been detected in bone marrow core biopsies using immunohistochemical techniques in patients achieving CR by conventional criteria. This study was designed to compare the prevalence of MRD with each agent in patients in CR by using conventional criteria and the relapse-free survival for patients with and without MRD. Bone marrow biopsies from 39 patients treated with a single cycle of 2-CdA and 27 patients treated with multiple cycles of 2'-DCF were studied. The monoclonal antibodies anti-CD20, DBA.44, and anti-CD45RO were used to evaluate the paraffin-embedded bone marrow core biopsies for MRD. Five of 39 patients (13%) treated with 2-CdA had MRD, as compared to 7 of 27 patients (26%) treated with 2'-DCF (two-tailed P = 0.21). Relapse has occurred in two of the five patients with MRD after 2-CdA treatment and in four of the seven patients with MRD after 2'-DCF treatment. In total, 6 of the 12 patients (50%) with MRD have relapsed, whereas 3 of 54 patients (6%) without MRD have relapsed, and 2 patients have died without evidence of relapse. The estimated 4-year relapse-free survival among patients with MRD is 55% (± 15%, SE), compared to 88% (± 5%, SE) among patients without MRD (two-tailed P = 0.0023). The prevalence of MRD detected in a subset of patients in CR after either 2-CdA or 2'-DCF treatment did not differ significantly. However, the presence of MRD is associated with an increased risk of relapse.

Original languageEnglish (US)
Pages (from-to)1665-1670
Number of pages6
JournalClinical Cancer Research
Volume5
Issue number7
StatePublished - Jul 1999

Fingerprint

Pentostatin
Cladribine
Hairy Cell Leukemia
Residual Neoplasm
Recurrence
Bone Marrow
Biopsy
Purine Nucleosides
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tallman, M. S., Hakimian, D., Kopecky, K. J., Wheaton, S., Wollins, E., Foucar, K., ... Peterson, L. C. (1999). Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse. Clinical Cancer Research, 5(7), 1665-1670.

Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse. / Tallman, Martin S.; Hakimian, David; Kopecky, Kenneth J.; Wheaton, Susan; Wollins, Eric; Foucar, Kathy; Cassileth, Peter A.; Habermann, Thomas Matthew; Grever, Michael; Rowe, Jacob M.; Peterson, LoAnn C.

In: Clinical Cancer Research, Vol. 5, No. 7, 07.1999, p. 1665-1670.

Research output: Contribution to journalArticle

Tallman, MS, Hakimian, D, Kopecky, KJ, Wheaton, S, Wollins, E, Foucar, K, Cassileth, PA, Habermann, TM, Grever, M, Rowe, JM & Peterson, LC 1999, 'Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse', Clinical Cancer Research, vol. 5, no. 7, pp. 1665-1670.
Tallman, Martin S. ; Hakimian, David ; Kopecky, Kenneth J. ; Wheaton, Susan ; Wollins, Eric ; Foucar, Kathy ; Cassileth, Peter A. ; Habermann, Thomas Matthew ; Grever, Michael ; Rowe, Jacob M. ; Peterson, LoAnn C. / Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 7. pp. 1665-1670.
@article{43eca4230b034b35b41da2ab30c2d547,
title = "Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse",
abstract = "The purine nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2'- deoxycoformycin (2'-DCF) induce complete remission (CR) in the majority of patients with hairy cell leukemia. However, minimal residual disease (MRD) has been detected in bone marrow core biopsies using immunohistochemical techniques in patients achieving CR by conventional criteria. This study was designed to compare the prevalence of MRD with each agent in patients in CR by using conventional criteria and the relapse-free survival for patients with and without MRD. Bone marrow biopsies from 39 patients treated with a single cycle of 2-CdA and 27 patients treated with multiple cycles of 2'-DCF were studied. The monoclonal antibodies anti-CD20, DBA.44, and anti-CD45RO were used to evaluate the paraffin-embedded bone marrow core biopsies for MRD. Five of 39 patients (13{\%}) treated with 2-CdA had MRD, as compared to 7 of 27 patients (26{\%}) treated with 2'-DCF (two-tailed P = 0.21). Relapse has occurred in two of the five patients with MRD after 2-CdA treatment and in four of the seven patients with MRD after 2'-DCF treatment. In total, 6 of the 12 patients (50{\%}) with MRD have relapsed, whereas 3 of 54 patients (6{\%}) without MRD have relapsed, and 2 patients have died without evidence of relapse. The estimated 4-year relapse-free survival among patients with MRD is 55{\%} (± 15{\%}, SE), compared to 88{\%} (± 5{\%}, SE) among patients without MRD (two-tailed P = 0.0023). The prevalence of MRD detected in a subset of patients in CR after either 2-CdA or 2'-DCF treatment did not differ significantly. However, the presence of MRD is associated with an increased risk of relapse.",
author = "Tallman, {Martin S.} and David Hakimian and Kopecky, {Kenneth J.} and Susan Wheaton and Eric Wollins and Kathy Foucar and Cassileth, {Peter A.} and Habermann, {Thomas Matthew} and Michael Grever and Rowe, {Jacob M.} and Peterson, {LoAnn C.}",
year = "1999",
month = "7",
language = "English (US)",
volume = "5",
pages = "1665--1670",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2'-deoxycoformycin and prediction of early relapse

AU - Tallman, Martin S.

AU - Hakimian, David

AU - Kopecky, Kenneth J.

AU - Wheaton, Susan

AU - Wollins, Eric

AU - Foucar, Kathy

AU - Cassileth, Peter A.

AU - Habermann, Thomas Matthew

AU - Grever, Michael

AU - Rowe, Jacob M.

AU - Peterson, LoAnn C.

PY - 1999/7

Y1 - 1999/7

N2 - The purine nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2'- deoxycoformycin (2'-DCF) induce complete remission (CR) in the majority of patients with hairy cell leukemia. However, minimal residual disease (MRD) has been detected in bone marrow core biopsies using immunohistochemical techniques in patients achieving CR by conventional criteria. This study was designed to compare the prevalence of MRD with each agent in patients in CR by using conventional criteria and the relapse-free survival for patients with and without MRD. Bone marrow biopsies from 39 patients treated with a single cycle of 2-CdA and 27 patients treated with multiple cycles of 2'-DCF were studied. The monoclonal antibodies anti-CD20, DBA.44, and anti-CD45RO were used to evaluate the paraffin-embedded bone marrow core biopsies for MRD. Five of 39 patients (13%) treated with 2-CdA had MRD, as compared to 7 of 27 patients (26%) treated with 2'-DCF (two-tailed P = 0.21). Relapse has occurred in two of the five patients with MRD after 2-CdA treatment and in four of the seven patients with MRD after 2'-DCF treatment. In total, 6 of the 12 patients (50%) with MRD have relapsed, whereas 3 of 54 patients (6%) without MRD have relapsed, and 2 patients have died without evidence of relapse. The estimated 4-year relapse-free survival among patients with MRD is 55% (± 15%, SE), compared to 88% (± 5%, SE) among patients without MRD (two-tailed P = 0.0023). The prevalence of MRD detected in a subset of patients in CR after either 2-CdA or 2'-DCF treatment did not differ significantly. However, the presence of MRD is associated with an increased risk of relapse.

AB - The purine nucleoside analogues 2-chlorodeoxyadenosine (2-CdA) and 2'- deoxycoformycin (2'-DCF) induce complete remission (CR) in the majority of patients with hairy cell leukemia. However, minimal residual disease (MRD) has been detected in bone marrow core biopsies using immunohistochemical techniques in patients achieving CR by conventional criteria. This study was designed to compare the prevalence of MRD with each agent in patients in CR by using conventional criteria and the relapse-free survival for patients with and without MRD. Bone marrow biopsies from 39 patients treated with a single cycle of 2-CdA and 27 patients treated with multiple cycles of 2'-DCF were studied. The monoclonal antibodies anti-CD20, DBA.44, and anti-CD45RO were used to evaluate the paraffin-embedded bone marrow core biopsies for MRD. Five of 39 patients (13%) treated with 2-CdA had MRD, as compared to 7 of 27 patients (26%) treated with 2'-DCF (two-tailed P = 0.21). Relapse has occurred in two of the five patients with MRD after 2-CdA treatment and in four of the seven patients with MRD after 2'-DCF treatment. In total, 6 of the 12 patients (50%) with MRD have relapsed, whereas 3 of 54 patients (6%) without MRD have relapsed, and 2 patients have died without evidence of relapse. The estimated 4-year relapse-free survival among patients with MRD is 55% (± 15%, SE), compared to 88% (± 5%, SE) among patients without MRD (two-tailed P = 0.0023). The prevalence of MRD detected in a subset of patients in CR after either 2-CdA or 2'-DCF treatment did not differ significantly. However, the presence of MRD is associated with an increased risk of relapse.

UR - http://www.scopus.com/inward/record.url?scp=0032766919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032766919&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 1665

EP - 1670

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -